Background Baricitinib (bari), an oral JAK1 and JAK2 inhibitor, was efficacious in Ph 3 studies in patients (pts) with active RA.1–4
Objectives To assess effects of bari on workplace and daily activity with the Work Productivity and Activity Impairment-Rheumatoid Arthritis (WPAI-RA) questionnaire in adult RA pts.
Methods In 4 Ph 3 trials (table), pts completed the WPAI-RA at baseline and ∼every 4 wks. Least-squares mean (LSM) of change from baseline was compared with ANCOVA.
Results Across studies, bari pts tended to have less absenteeism, presenteeism, and impairment in work productivity and daily activities at primary and final timepoints vs pts from comparator groups.
Conclusions Across 4 Ph 3 studies, bari treatment improved workplace and daily activities in RA pts.
Dougados et al. Ann Rheum Dis 2015;
Genovese et al. Ann Rheum Dis 2015;
Taylor et al. Arthritis Rheumatol 2015;
Fleischmann et al. Arthritis Rheumatol 2015
Disclosure of Interest J. Smolen Grant/research support from: AbbVie, Janssen, MSD, Pfizer, Roche, UCB, Consultant for: AbbVie, Amgen, Astra-Zeneca, Astro, Celgene, Glaxo, Janssen, Lilly, Medimmune, MSD, Novartis-Sandoz, Pfizer, Roche, Samsung, Sanofi, UCB, A. DeLozier Employee of: Eli Lilly and Company, S. de Bono Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, L. Yang Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, C. Gaich Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company